LUND, SE / ACCESS Newswire / May 22, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today comments on a recent update shared by Shanghai Henlius Biotech, Inc. regarding long-term follow-up ...
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its ...
Late-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company’s targeted protein degradation platform, in relapsed or refractory multiple ...
TORONTO, ON / ACCESS Newswire / May 21, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") is pleased to announce the voting results from its annual general and special meeting of ...
WINNIPEG, MB / ACCESS Newswire / May 21, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and ...
Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced that the company has received approval from the KRX to proceed with its ...
A randomized, controlled study of a novel liquid embolic, NeoCast, adjunctive to surgeryWALTHAM, Mass.--(BUSINESS WIRE)--Arsenal Medical, a clinical-stage company developing innovative ...
The Law Offices of Frank R. Cruz announces an investigation of Phreesia Inc. (“Phreesia” or the “Company”) (NYSE: PHR) on behalf of investors concerning the Company’s possible violations of federal ...
Advicenne (Euronext Growth Paris - FR0013296746 -ALDVI), a pharmaceutical company specializing in the development and marketing of innovativetreatments for people suffering from rare kidney diseases, ...
ETX-19477 demonstrated robust efficacy, with a 57% objective response rate in BRCA-mutated platinum-resistant ovarian cancer and earlier-line HR+/HER2- breast cancer (n=7) ---- Favorable safety ...
Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors to be presented –ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced ...
AI-powered pre-screening infrastructure enables scalable, privacy-preserving clinical trial matching across underserved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results